News Pfizer might buy BMS for $130bn – but should it? Pfizer could soon launch a multi-billion dollar bid for immunotherapy rivals Bristol-Myers Squibb.
News BMS strikes back with lung cancer combo success Just as it looked like Bristol Myers Squibb might never catch up with its rivals in frontline lung cancer treatment, the company has achieved success in a new combination.
News BMS and Infinity aim to overcome triple negative breast canc... BMS is looking to get ahead of its rival Merck & Co. by overcoming resistance to PD-1 immunotherapy in triple negative breast cancer patients.
News BMS and Roche look to Halozyme drug delivery for IO advantag... Bristol-Myers Squibb is to work with drug delivery specialist Halozyme to create an injectable form of its blockbuster immunotherapy Opdivo.
News Clovis and BMS combine cancer drugs in late-stage trials Clovis and BMS research small molecule and antibody combination.
Views & Analysis The cancer challenge: the quest for a cure is only half the ... The cancer challenge is affecting more and more people worldwide, with 21 million cases expected by 2030.
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
